GOG-9926

Terminated

Return to Protocol Table

A Phase I Evaluation of Extended Field Radiation Therapy with Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women with Cervical Carcinoma Metastatic to the Para-Aortic Lymph Nodes

Principal Investigator

Cecelia Boardman

Status

Terminated

Open to Accrual

April 4, 2011

Closed to Accrual & Treatment

April 4, 2011

Closed to Accrual & Treatment

May 19, 2014

Terminated

February 9, 2019


Disease Site

Gynecologic [GY] Cervix

Phase

I

Developmental Therapeutics

No

Primary Objective

To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of adjuvant carboplatin and paclitaxel chemotherapy following concurrent weekly cisplatin chemotherapy and extended field radiation in women with newly diagnosed Stage IB-IVA cervical cancer, with positive para-aortic nodes.

To determine the feasibility of the treatment regimen over the four cycles of adjuvant chemotherapy once the MTD in estimated.

To assess the toxicities of the treatment regimen the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.

Patient Population

Women with newly diagnosed Stage IB-IVA cervical cancer, with positive para-aortic nodes.

Target Accrual

18

Patient Study Webpage

There is no available patient study webpage available for this trial at this time.